26,571 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 26,571 shares of the biotechnology company’s stock, valued at approximately $164,000.

Several other large investors have also recently modified their holdings of the company. Northeast Financial Consultants Inc raised its stake in shares of BioCryst Pharmaceuticals by 8.2% during the 2nd quarter. Northeast Financial Consultants Inc now owns 65,633 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 5,000 shares in the last quarter. Creative Planning raised its stake in shares of BioCryst Pharmaceuticals by 75.2% during the 2nd quarter. Creative Planning now owns 46,613 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 20,014 shares in the last quarter. Algert Global LLC grew its position in BioCryst Pharmaceuticals by 18.6% during the 2nd quarter. Algert Global LLC now owns 353,133 shares of the biotechnology company’s stock worth $2,182,000 after purchasing an additional 55,311 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in BioCryst Pharmaceuticals by 113.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 212,581 shares of the biotechnology company’s stock worth $1,314,000 after purchasing an additional 113,152 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its position in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after purchasing an additional 3,140,804 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $7.62 on Monday. The firm’s fifty day simple moving average is $7.81 and its 200-day simple moving average is $6.68. The company has a market capitalization of $1.57 billion, a P/E ratio of -7.12 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to analysts’ expectations of $98.30 million. During the same period last year, the company earned ($0.24) earnings per share. The firm’s revenue was up 34.9% on a year-over-year basis. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.